K-Biopharmaceutical Exports Reach USD 2 Billion in Q1, Setting Quarterly Record
Up 11.1% Year-on-Year
Swiss Exports Surge 70% to Take Top Spot
From January to March of this year, Korea's exports of biopharmaceutical products reached a record high of USD 2 billion (approximately KRW 3 trillion).
According to the Ministry of Food and Drug Safety on April 10, biopharmaceutical exports in the first quarter of 2026 were provisionally tallied at USD 2 billion, up 11.1% from the same period last year. This follows USD 1.5 billion in the first quarter of 2024 and USD 1.8 billion in the first quarter of 2025, marking three consecutive years of growth and the highest quarterly performance ever recorded.
The increase in market share of Korean biopharmaceutical products globally, as well as the enhanced competitiveness of the contract development and manufacturing organization (CDMO) sector, are cited as the main drivers behind this performance.
In the first quarter of this year, biopharmaceutical products accounted for 71% of the total pharmaceutical exports, which stood at USD 2.8 billion.
By month, exports in January and February rose to USD 660 million and USD 690 million, up 11.9% and 25.4% year-on-year, respectively, while exports in March were USD 650 million, a similar figure to the same period last year, indicating stable export levels throughout the quarter.
By country, Switzerland ranked first with USD 340 million (17.0% of total exports), surging 70% from USD 200 million in the same period last year and moving up from fourth to first place. The United States ranked second with USD 330 million (16.5%), although this represented a decrease of USD 40 million from the previous year. Hungary placed third with USD 300 million (15.0%), up USD 50 million from a year earlier. The top five countries—Switzerland, the United States, Hungary, Germany, and the Netherlands—accounted for 68.4% of total exports.
The increase in exports to Europe is attributed to a combination of greater collaboration and technology transfers with global pharmaceutical companies and a favorable environment for biosimilars.
In response to the rapid growth of the CDMO market, the Ministry of Food and Drug Safety enacted the "Special Act on Regulatory Support for Biopharmaceutical CDMO Companies" in December last year. Scheduled to take effect in December this year, this law introduces an export manufacturing registration system, enabling CDMO companies to enter global markets without the need for a pharmaceutical manufacturing license.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The ministry is also working to streamline overseas expansion procedures for domestic biopharmaceutical companies by reducing the number of required documents for preliminary GMP evaluation from 11 to 4 and launching a "pilot project for certification of raw material manufacturing facilities," among other initiatives.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.